154 related articles for article (PubMed ID: 16552791)
1. Rules and laws of drug hepatotoxicity.
Kaplowitz N
Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):231-3. PubMed ID: 16552791
[No Abstract] [Full Text] [Related]
2. Hy's law: predicting serious hepatotoxicity.
Temple R
Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):241-3. PubMed ID: 16552790
[No Abstract] [Full Text] [Related]
3. How can 'Hy's law' help the clinician?
Senior JR
Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):235-9. PubMed ID: 16552792
[No Abstract] [Full Text] [Related]
4. 'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective.
Lewis JH
Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):221-9. PubMed ID: 16444771
[No Abstract] [Full Text] [Related]
5. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience.
Goldkind L; Laine L
Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):213-20. PubMed ID: 16456879
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced hepatotoxicity.
Lee WM
N Engl J Med; 2003 Jul; 349(5):474-85. PubMed ID: 12890847
[No Abstract] [Full Text] [Related]
7. Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction.
Maniratanachote R; Shibata A; Kaneko S; Yamamori I; Wakasugi T; Sawazaki T; Katoh K; Tokudome S; Nakajima M; Yokoi T
Toxicology; 2005 Dec; 216(1):15-23. PubMed ID: 16115720
[TBL] [Abstract][Full Text] [Related]
8. From the Food and Drug Administration.
Nightingale SL
JAMA; 1997 Dec; 278(21):1728. PubMed ID: 9388135
[No Abstract] [Full Text] [Related]
9. Ontology-based knowledge management of troglitazone-induced hepatotoxicity.
Hug H; Dannecker R; Schindler R; Bagatto D; Stephan A; Wess RA; Gut J
Drug Discov Today; 2004 Nov; 9(22):948-54. PubMed ID: 15539136
[No Abstract] [Full Text] [Related]
10. Troglitazone (Rezulin) and hepatic injury.
Faich GA; Moseley RH
Pharmacoepidemiol Drug Saf; 2001; 10(6):537-47. PubMed ID: 11828837
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone and liver injury: in search of answers.
Chojkier M
Hepatology; 2005 Feb; 41(2):237-46. PubMed ID: 15657914
[No Abstract] [Full Text] [Related]
12. Serious liver injury. Leading reason for drug removals, restrictions.
Meadows M
FDA Consum; 2001; 35(3):8-9. PubMed ID: 11458559
[No Abstract] [Full Text] [Related]
13. Hepatotoxicity of the thiazolidinediones.
Tolman KG; Chandramouli J
Clin Liver Dis; 2003 May; 7(2):369-79, vi. PubMed ID: 12879989
[TBL] [Abstract][Full Text] [Related]
14. Lessons from the glitazones: a story of drug development.
Gale EA
Lancet; 2001 Jun; 357(9271):1870-5. PubMed ID: 11410214
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone and cardiovascular risk.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
[No Abstract] [Full Text] [Related]
16. Avoiding hepatic injury from drugs.
Kaplowitz N
Gastroenterology; 1999 Oct; 117(4):759. PubMed ID: 10500055
[No Abstract] [Full Text] [Related]
17. Troglitazone.
Yokoi T
Handb Exp Pharmacol; 2010; (196):419-35. PubMed ID: 20020270
[TBL] [Abstract][Full Text] [Related]
18. Rezulin to be withdrawn from the market.
Diabetes Technol Ther; 2000; 2(2):289. PubMed ID: 11469272
[No Abstract] [Full Text] [Related]
19. Troglitazone-associated hepatic failure.
Booth AM; Caldwell SH; Iezzoni JC
Am J Gastroenterol; 2000 Feb; 95(2):557-8. PubMed ID: 10685776
[No Abstract] [Full Text] [Related]
20. Rosiglitazone: what went wrong?
Cohen D
BMJ; 2010 Sep; 341():c4848. PubMed ID: 20819889
[No Abstract] [Full Text] [Related]
[Next] [New Search]
